Lexeo Therapeutics Inc. (NASDAQ:LXEO) faces price target cuts from H.C. Wainwright and Leerink due to recent equity raises, with potential gross proceeds of $135 million. The company aims to strengthen its balance sheet before pivotal trials. LXEO focuses on genetic medicine for hereditary and acquired diseases in the US.

Despite potential investment in LXEO, AI stocks may offer greater upside with less risk. For those seeking undervalued AI stocks, consider options that could benefit from current economic trends. Learn more about AI stocks with significant potential in our free report.

For more stock options with high growth potential, explore “30 Stocks That Should Double in 3 Years” and “11 Hidden AI Stocks to Buy Right Now.” This article is originally published on Insider Monkey.

Read more at Yahoo Finance: Lexeo Therapeutics (LXEO) Gets a PT Cut to $13 by H.C. Wainwright Due to Equity Raise